Alembic Pharmaceuticals Intrinsic Value

Alembic Pharmaceuticals intrinsic value. Alembic Pharmaceuticals (APLLTD) median intrinsic value is ₹2099.20 from 10 valuation models (range ₹436–₹2624), vs current price ₹1049.60 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. For current market price and key ratios, visit Alembic Pharmaceuticals screener.

Market Price (CMP)
₹1049.60
Primary Intrinsic Value
₹1500.40
Market Cap
₹4093 Cr
+100.0% Upside
Median Value
₹2099.20
Value Range
₹436 - ₹2624
Assessment
Trading Below Calculated Value
Safety Margin
50.0%

APLLTD Valuation Methods Summary — DCF, Graham Number & P/E

Alembic Pharmaceuticals intrinsic value across 10 models vs current price ₹1049.60 — upside/downside and value range per method. Analyse Alembic Pharmaceuticals ownership pattern to track promoter, FII and institutional holdings.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹1500.40 ₹1200.32 - ₹1800.48 +42.9% EPS: ₹68.20, Sector P/E: 22x
Book Value Method asset ₹2624.00 ₹2361.60 - ₹2886.40 +150.0% Book Value/Share: ₹1453.59, P/B: 2.0x
Revenue Multiple Method revenue ₹2099.20 ₹1889.28 - ₹2309.12 +100.0% Revenue/Share: ₹2686.15, P/S: 2.0x
EBITDA Multiple Method earnings ₹2099.20 ₹1889.28 - ₹2309.12 +100.0% EBITDA: ₹2308.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹2186.56 ₹1749.25 - ₹2623.87 +108.3% CF Growth: 9.1%, Discount: 15%
PEG Ratio Method growth ₹436.48 ₹392.83 - ₹480.13 -58.4% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹1053.69 ₹948.32 - ₹1159.06 +0.4% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹2099.20 ₹1889.28 - ₹2309.12 +100.0% ROE: 23.6%, P/E Multiple: 16x
Graham Defensive Method conservative ₹1493.50 ₹1344.15 - ₹1642.85 +42.3% EPS: ₹68.20, BVPS: ₹1453.59
Dividend Yield Method dividend ₹480.00 ₹432.00 - ₹528.00 -54.3% DPS: ₹12.00, Target Yield: 2.5%
Method Types: Earnings Asset DCF Growth Dividend Conservative

APLLTD Intrinsic Value vs Market Price — All Valuation Models

Alembic Pharmaceuticals fair value range ₹436–₹2624 vs current market price ₹1049.60 across 10 valuation models. Browse Alembic Pharmaceuticals annual reports for revenue, profit, balance sheet and cash flow data.

APLLTD Intrinsic Value Analysis — Undervalued or Overvalued?

Alembic Pharmaceuticals median intrinsic value ₹2099.20, current price ₹1049.60 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.

What is the intrinsic value of APLLTD?

Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Alembic Pharmaceuticals (APLLTD) is ₹2099.20 (median value). With the current market price of ₹1049.60, this represents a +100.0% variance from our estimated fair value.

The valuation range spans from ₹436.48 to ₹2624.00, indicating ₹436.48 - ₹2624.00.

Is APLLTD undervalued or overvalued?

Based on our multi-method analysis, Alembic Pharmaceuticals (APLLTD) appears to be trading below calculated value by approximately 100.0%.

APLLTD Financial Health — Key Ratios vs Industry Benchmarks

Alembic Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 23.6% Industry Standard: 15%+ Above 15% Measures shareholder return efficiency
Operating Margin 22.0% Industry Standard: 20%+ Above 20% Indicates operational efficiency level
Asset Turnover Ratio 1.20x Industry Standard: 1.0x+ Above 1.0x Measures asset utilization efficiency

APLLTD Cash Flow Quality — Operating & Free Cash Flow

Alembic Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹783 Cr ₹530 Cr Positive Free Cash Flow 8/10
March 2025 ₹88 Cr ₹-196 Cr Positive Operating Cash Flow 6/10
March 2024 ₹803 Cr ₹643 Cr Positive Free Cash Flow 8/10
March 2023 ₹724 Cr ₹500 Cr Positive Free Cash Flow 8/10
March 2022 ₹552 Cr ₹366 Cr Positive Free Cash Flow 8/10